Alliancebernstein L.P. reduced its holdings in shares of Hologic (NASDAQ:HOLX) by 27.1% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,779,442 shares of the medical equipment provider’s stock after selling 661,113 shares during the period. Alliancebernstein L.P. owned about 0.64% of Hologic worth $76,071,000 at the end of the most recent reporting period.
Several other institutional investors have also modified their holdings of HOLX. Grove Bank & Trust boosted its position in shares of Hologic by 115.8% during the 3rd quarter. Grove Bank & Trust now owns 2,860 shares of the medical equipment provider’s stock valued at $105,000 after acquiring an additional 1,535 shares in the last quarter. NuWave Investment Management LLC acquired a new stake in shares of Hologic during the 4th quarter valued at about $199,000. Fiduciary Trust Co. acquired a new stake in shares of Hologic during the 4th quarter valued at about $208,000. Advisor Partners LLC acquired a new stake in shares of Hologic during the 4th quarter valued at about $209,000. Finally, MPS Loria Financial Planners LLC acquired a new stake in shares of Hologic during the 4th quarter valued at about $214,000. Institutional investors and hedge funds own 97.56% of the company’s stock.
NASDAQ:HOLX traded down $0.72 on Monday, reaching $36.64. The stock had a trading volume of 2,112,077 shares, compared to its average volume of 2,634,405. Hologic has a 1-year low of $35.33 and a 1-year high of $46.80. The firm has a market cap of $10,331.13, a PE ratio of 18.05, a price-to-earnings-growth ratio of 1.68 and a beta of 0.85. The company has a quick ratio of 0.98, a current ratio of 1.25 and a debt-to-equity ratio of 0.87.
Hologic (NASDAQ:HOLX) last announced its earnings results on Thursday, February 8th. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.50 by $0.05. Hologic had a net margin of 34.53% and a return on equity of 20.07%. The company had revenue of $791.10 million for the quarter, compared to analyst estimates of $785.80 million. During the same period in the prior year, the business earned $0.52 earnings per share. Hologic’s quarterly revenue was up 7.7% on a year-over-year basis. research analysts expect that Hologic will post 2.25 EPS for the current fiscal year.
Several analysts have recently weighed in on the stock. Needham & Company LLC reiterated a “buy” rating and set a $50.00 target price (up from $48.00) on shares of Hologic in a research report on Tuesday, January 9th. Deutsche Bank lowered shares of Hologic from a “buy” rating to a “hold” rating and set a $49.00 target price on the stock. in a research report on Friday, January 19th. BidaskClub lowered shares of Hologic from a “hold” rating to a “sell” rating in a research report on Saturday, January 13th. Cowen upgraded shares of Hologic to a “buy” rating and set a $52.00 price target on the stock in a research report on Wednesday, December 20th. Finally, Bank of America upgraded shares of Hologic from a “neutral” rating to a “buy” rating and set a $50.00 price target on the stock in a research report on Thursday, January 4th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and nine have issued a buy rating to the stock. Hologic has an average rating of “Buy” and a consensus target price of $47.21.
In related news, Director Charles J. Dockendorff bought 13,000 shares of Hologic stock in a transaction dated Thursday, March 15th. The shares were bought at an average cost of $38.80 per share, for a total transaction of $504,400.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Namal Nawana purchased 6,600 shares of the company’s stock in a transaction that occurred on Tuesday, February 13th. The shares were acquired at an average cost of $37.88 per share, with a total value of $250,008.00. Following the completion of the purchase, the director now owns 6,954 shares of the company’s stock, valued at $263,417.52. The disclosure for this purchase can be found here. 0.88% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by Enterprise Leader and is owned by of Enterprise Leader. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://theenterpriseleader.com/2018/04/02/alliancebernstein-l-p-has-76-07-million-position-in-hologic-inc-nasdaqholx.html.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.